Showing 4671-4680 of 5910 results for "".
- Notal Vision Announces Publication First Prospective Longitudinal Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-first-prospective-longitudinal-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479365/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in
- Notal Vision Announces Publication of First Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-of-first-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479356/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated home OCT for wet age-related macular degeneration
- Belkin Laser Announces Corporate Name Change to Belkin Visionhttps://modernod.com/news/belkin-laser-announces-corporate-name-change-to-belkin-vision/2479352/Israel-based medical device company Belkin Laser announced that it will begin operating under the new name of Belkin Vision. The name change is a strategic decision that will better reflect the company’s capability to solve future ophthalmic challenges, according to a company stateme
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eyehttps://modernod.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/NovaSight announced that it has reached several key milestones that signal progress toward the launch of its CureSight digital treatment device for amblyopia (lazy eye) and the establishment of a reimbursement structure for the physicians and patients who use it. NovaSight took an importan
- Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 3 Trial of Zimura in GA Secondary to AMDhttps://modernod.com/news/iveric-bio-receives-fda-agreement-under-special-protocol-assessment-spa-for-phase-3-trial-of-zimura-in-ga-secondary-to-amd/2479341/Iveric bio announced that the company received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the company’s pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to a
- CVC Capital Partners VIII to Acquire Majority Stake in Raynerhttps://modernod.com/news/cvc-capital-partners-viii-to-invest-in-rayner/2479340/CVC Capital Partners VIII announced that it has agreed to acquire a majority interest in Rayner, the global ophthalmology business from UK-based private equity firm Phoenix Equity Partners. Terms of the deal were not disclosed. The transaction is expected to close in the third quar
- Nicox to Receive $2 Million from Ocumension as Milestone Payment Under Zerviate Agreementhttps://modernod.com/news/nicox-to-receive-2-million-from-ocumension-as-milestone-payment-under-zerviate-agreement/2479339/Nicox announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amend
- Ocular Therapeutix and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry AMDhttps://modernod.com/news/ocular-therapeutix-and-mosaic-biosciences-enter-into-strategic-discovery-collaboration-targeting-the-treatment-of-dry-age-related-macular-degeneration/2479331/Ocular Therapeutix entered into a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents aimed at the treatment of dry age-related macular degeneration (AMD). Ocular Therapeutix has agreed to fund the research performed under the collaboration and re
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr